Previous 10 | Next 10 |
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that Chief Financial Officer Tran B. Nguyen has bee...
According to a recent report from MarketsAndMarkets.com, the global Parkinson’s disease treatment market is expected to reach $5.69 billion by 2022, growing from $4.24 billion in 2017, expanding at a CAGR of 6.1%. The report notes that this market is being driven by rising geriat...
When a biotech company develops a drug candidate that can help millions of people fight a monstrous disease such as Alzheimer's, it will certainly gain attention from scientists, the news media, and the U.S. Food and Drug Administration. For Prothena (NASDAQ: PRTA) , a huge wave...
Prothena Corporation plc (NASDAQ:PRTA) traded at a new 52-week high today of $75.38. So far today approximately 164,000 shares have been exchanged, as compared to an average 30-day volume of 373,000 shares. Prothena Corp PLC is a biotechnology company focuses on the discovery, developmen...
Prothena Corporation plc (NASDAQ:PRTA) traded today at a new 52-week high of $73.50. So far today approximately 164,000 shares have been exchanged, as compared to an average 30-day volume of 373,000 shares. Prothena Corp PLC is a biotechnology company focuses on the discovery, developmen...
DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will par...
Shares of Prothena Corporation plc (NASDAQ:PRTA) traded at a new 52-week high today of $71.59. So far today approximately 164,000 shares have been exchanged, as compared to an average 30-day volume of 364,000 shares. Prothena Corp PLC is a biotechnology company focuses on the discovery, ...
Prothena Corporation plc (NASDAQ:PRTA) traded at a new 52-week high today of $69.00. Approximately 164,000 shares have changed hands today, as compared to an average 30-day volume of 356,000 shares. Potential upside of 47.4% exists for Prothena Corporation plc, based on a current level o...
Electric vehicle stocks are lower to start the week as more regulatory grumblings from Beijing impact the sector. State media in China is reporting regulations on online games could be tightened to ensure they don't misrepresent history. That does not directly impact EV manufacturers, but is ...
Prothena (NASDAQ:PRTA): Q2 GAAP EPS of $0.58 misses by $0.30. Revenue of $60.07M (+31515.8% Y/Y) misses by $13.47M. Press Release For further details see: Prothena EPS misses by $0.30, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...